Researchers at Northwell Health in New Hyde Park, N.Y., are testing famotidine in high intravenous doses as a potential COVID-19 treatment.
Shortly after the hospital announced the clinical trial, Amazon, Walgreens and CVS all reported shortages of the drug, sold under the brand name Pepcid.
Teva Pharmaceutical, Carlsbad Technology and Aurobindo Pharma have all reported increased demand for famotidine, according to Bloomberg.
The shortage comes just over a month after the FDA asked drugmakers to pull supplies of another common heartburn drug, ranitidine, off shelves after finding it contained unacceptably high levels of a carcinogen.
Read the full article here.
More articles on pharmacy:
FDA clarifies relaxed compounding rules for pharmacies
Gilead gets FDA emergency use authorization for remdesivir
AmerisourceBergen offers to buy Walgreens’ drug wholesaling division
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
